贵阳口、鼻、咽、喉内侧面血管神经模型呼和浩特显像引导下中心静脉穿刺模型,山东猪子宫解剖模型,开放式诊断学辅助教学系统多少钱,西安透明肾脏模型,成都高级全功能老年护理人（女性）,内蒙古灾难现场应急救护智能模拟训练系统,辽阳产后出血训练模型

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BERLIN, June 9 (Xinhua) -- A 57-year-old man died of E. coli infection in Germany's Frankfurt Thursday, pushing the death toll from the bacteria to 30.The man had traveled with his wife to the city of Hamburg, an epicenter of the outbreak, Frankfurt authority said.Another two deaths were reported in the state of Lower Saxony, including a 68-year-old man and a 20-year-old woman, while more than 2,800 people in 14 countries have been infected since the deadly E. coli outbroke.German researchers detected again the deadly strain o104 of E. coli on the scraps of cucumbers in a dustbin in the eastern city of Magdeburg in the state Saxony-Anhalt on Wednesday.German health minister Daniel Bahr expressed his cautious hope for the disease on Wednesday as the number of new infection is clearly going down.But he also admitted there will be new cases and more deaths have to be expected, as Germany's national disease control centre, the Robert Koch Institute reported more than 300 infection in Germany on the same day.The Robert Koch Institute also noticed the declining trend in new cases but it was not clear whether this was caused by people staying away from vegetables or the outbreak was truly waning.

BEIJING, Sept. 8 (Xinhuanet) -- Middle-aged white women drinking alcohol moderately are more likely to stay healthy than nondrinkers, according to a new study from Harvard.The study has followed about 14,000 mostly white women since 1976.As a result, compared with teetotalers, those who had 3 to 15 alcoholic drinks weekly in their late 50s were 28 percent higher of being free from physical disability, chronic illness, mental health problems, and cognitive decline at the age of 70.Even having just one or two drinks per week increased a woman's odds of good health by 11 percent.However, women should be aware that even moderate drinking has been linked to an increased risk of breast cancer, said Qi Sun, M.D., a lead author of the study and a nutrition researcher at the Harvard School of Public Health.These findings don't necessarily apply to men or to nonwhite women. But they reinforced the evidence for the health benefits of moderate drinking.

MOSCOW, Aug. 7 (Xinhua) -- A state of emergency has been imposed in a district in the Krasnodar Region in south Russia amid an out break of the African swine fever, the regional emergencies center said on Sunday.The emergencies center told local reporters that the African swine fever virus (ASFV) was found in a private farm where 15 pigs died of the disease, but the source of the infection is still unclear.Local authorities said some 12,000 pigs in and around the Krylovskaya village, some three km away from the private farm, are being culled, 50 of which have already died of the ASFV in recent days.In April, the regional emergencies has temporarily declared a state of emergency in the Labinsky district in the region, as the ASFV was found at a livestock farm. 85 pigs were culled at the farm.